Starting a highly effective treatment for relapsing-remitting multiple sclerosis (MS) soon after diagnosis is superior to starting an older, first-line agent and then escalating treatment, new research...

The investigational drug tolebrutinib effectively reduces brain lesions in patients with highly active relapsing-remitting multiple sclerosis (RRMS), new research suggests. After 12 weeks of treatment,...

Multiple sclerosis (MS) affects Whites, African Americans, and Hispanics differently, a new study finds, and there are big gaps in how they respond to disease-modifying therapies (DMTs). “Hispanics...